Donepezil Market Size is USD 921.55 Million in 2026

The global donepezil market, valued at USD 906.15 million in 2025, is projected to reach approximately USD 1,072.03 million by 2035. This steady growth, driven by increasing use in functional foods, nutraceuticals, and pharmaceuticals, is expected at a CAGR of 1.70%.

Donepezil Market Statical Scope

The donepezil market is expanding steadily due to the rising geriatric population and the growing burden of neurodegenerative diseases. Donepezil, a cholinesterase inhibitor, plays a crucial role in improving memory and cognitive function in patients with mild to moderate Alzheimer’s. The market benefits from strong healthcare infrastructure in developed regions and the increasing availability of cost-effective generic formulations in emerging economies. However, limited efficacy in advanced stages of the disease and potential side effects such as nausea and insomnia act as key restraints. Moreover, competition from novel Alzheimer’s drugs and ongoing research into disease-modifying treatments may impact long-term demand.
 
Despite these challenges, opportunities exist in expanding therapeutic indications for donepezil, such as in vascular dementia and Parkinson’s-related cognitive decline. Growing healthcare investments and the rising focus on early diagnosis are also expected to enhance market penetration in the coming years.
The donepezil market is anticipated to grow more rapidly as pharmaceutical companies adopt artificial intelligence AI-driven approaches in drug discovery, clinical trial optimization, and patient stratification. Artificial intelligence enables faster analysis of biological data to identify responders and optimize dosage regimens for better therapeutic outcomes. 

Donepezil Market Share, By Region, 2025 (%)

• North America (33.27%) - The dominant regional market, supported by high Alzheimer’s prevalence, advanced healthcare infrastructure, and strong pharmaceutical presence.
• Europe (23.96%) - A well-established market with strong healthcare systems and growing elderly population, though slightly behind North America in adoption.
• Asia Pacific (27.89%) - A rapidly growing region driven by rising geriatric population, increasing awareness, and expanding access to neurological treatments.
• LAMEA (14.88%) - The smallest market, with gradual growth supported by improving healthcare access but limited by lower diagnosis and treatment rates.

Donepezil Market Share, By Type, 2025 (%)

• 5mg (46.32%) - The most commonly prescribed dosage of donepezil, widely used as the initial treatment for mild to moderate Alzheimer’s disease due to better tolerability.
• 10mg (38.91%) - A higher maintenance dose used for moderate to severe Alzheimer’s patients, offering improved efficacy but with slightly increased side-effect risks.
• 23mg (14.77%) - A specialized high-dose formulation reserved for advanced Alzheimer’s cases, with limited usage due to tolerability concerns and stricter prescription practices.

Donepezil Market Share, By Application, 2025 (%)

• Hospitals (41.18%) - The leading application segment, where patients receive diagnosis, initial prescriptions, and monitored treatment for Alzheimer’s disease.
• Clinics (28.74%) - A significant segment driven by outpatient care and follow-up consultations, but smaller than hospitals due to limited advanced care facilities.
• Drugstore (30.08%) - A strong distribution channel as patients rely on retail pharmacies for regular medication refills, contributing notably to market share.